Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 03, 2019
PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells.
Journal: Journal of cellular and molecular medicine
Published: July 17, 2012
Showing 1-2 of 2
Last Updated: 09/26/2026